ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0891

Rheumatoid Arthritis and the Rheumatic Disease Comorbidity Index (RDCI): Its Impact on Disease Activity

Sultana Abdulaziz1, Suzan Attar2, Renad Ahmed2, Hamza Fida2, Omar Bokhary2, Anas Alyazidi2 and Abdulelah Abumohssin2, 1King Fahad Hospital, Jeddah, Saudi Arabia, 2King Abdulaziz University, Jeddah, Saudi Arabia

Meeting: ACR Convergence 2022

Keywords: Anti-CCP, HAQ, Health Assessment Questionnaire (HAQ), rheumatoid arthritis, Rheumatoid Factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Comorbid conditions in the setting of rheumatoid arthritis (RA) play an important role in predicting disease activity and functional impairment (1). Application of a specific comorbidity index in a clinical setting could be useful in identifying patients with a poor prognosis (2). The rheumatic disease comorbidity index (RDCI) is a scoring system developed specifically for RA patients that is used to assess their total burden of comorbidity (2). The application of RDCI has not yet been well documented in published literature, and the clinical presentations and comorbidities of RA patients have not been adequately described in the local region. Our study aims to assess the relationship between comorbidity and disease activity of RA by use of the RDCI.

Methods: Between 2019 and 2021, medical records and clinical data from the latest rheumatology clinic visit of consecutive RA outpatients above 18 years of age were reviewed in a two-center retrospective study. Data retrieved included demographics, clinical presentation, inflammatory markers, comorbid conditions, and medications. RDCI was calculated for each patient, and disease activity was assessed using disease activity score 28 (DAS28), clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) scores. The degree of functional impairment was documented using the health assessment questionnaire (HAQ).

Results: 195 patients were included in this study. Most of the study population was female, with a mean age of 55 years, and an average body mass index (BMI) of 31. The most prevalent comorbidity was hypertension (29.7%). A large portion of patients had an RDCI score of zero (38.5%) with the second largest group scoring 3 or higher (22.1%). The mean DAS 28 CRP score was 3.34 (± 1.2), with 49.3% of patients achieving a good EULAR response, while the mean CDAI score was 13.8 ± 10.3 with only 19 (9.9%) patients achieving the same response. Patients with a higher RDCI score were older (p < 0.001) with a longer duration of disease (p < 0.001) and significantly higher HAQ scores (p = 0.012). However, no association between RDCI scores and disease activity was found. Independent predictors of a good clinical response were decreasing BMI and the use of tumor necrosis factor-inhibiting medications.

Conclusion: Although a direct relationship between RDCI score and disease activity could not be established, it did have a significant impact on functional impairment. We recommend that routine calculation of RDCI scores could prove useful in identifying multimorbid RA patients with a poor prognosis and help in fine adjustment of treatment goals to restore quality of life.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: S. Abdulaziz, None; S. Attar, None; R. Ahmed, None; H. Fida, None; O. Bokhary, None; A. Alyazidi, None; A. Abumohssin, None.

To cite this abstract in AMA style:

Abdulaziz S, Attar S, Ahmed R, Fida H, Bokhary O, Alyazidi A, Abumohssin A. Rheumatoid Arthritis and the Rheumatic Disease Comorbidity Index (RDCI): Its Impact on Disease Activity [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/rheumatoid-arthritis-and-the-rheumatic-disease-comorbidity-index-rdci-its-impact-on-disease-activity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-arthritis-and-the-rheumatic-disease-comorbidity-index-rdci-its-impact-on-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology